arrow
Return

Vitiligo

delete2025-12-04
delete0
PRE
AI
J
Julien Sénéschal *
J
Jung Min Bae
K
Khaled Ezzedine
I
Iltefat Hamzavi
J
John E. Harris
B
Barbara Bellei
D
Davinder Parsad
T
Thierry Passeron
N
Nanja van Geel
K
Katia Boniface
M
Mauro Picardo
DOI:10.1038/s41572-025-00670-xdelete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Vitiligo is an acquired autoimmune depigmenting disorder that affects approximately 0.36% of the global population and presents in three forms based on lesion distribution: non-segmental, segmental and mixed vitiligo. Beyond its visible impact on the skin, vitiligo deeply affects mental well-being and quality of life. The pathogenesis of non-segmental vitiligo is influenced by genetic polymorphisms that are linked to immune response and melanogenesis pathways, whereas environmental factors contribute to disease onset. Diagnosis is generally clinical, with laboratory tests or biopsies rarely required. Melanocyte loss involves mechanisms, such as cellular stress, innate immune activation and adaptive immune responses, that specifically target melanocytes, with a central role for tissue-resident memory T cells. This cascade ultimately leads to the depletion of epidermal melanocytes and impairs melanocyte stem cell regeneration. Clinical management emphasizes shared decision-making with three primary objectives: halting depigmentation, initiating repigmentation and sustaining pigment restoration. Signs of active disease help clinicians to identify patients in need of intervention. Treatments approved in the past 2 years offer potential for reversing disease progression, and emerging therapies targeting key pathways to modulate immune activation and stimulate melanocyte regeneration and differentiation are being tested in clinical trials. Vitiligo is a chronic, autoimmune, depigmenting disorder that has both physiological and psychological effects on affected individuals. In this Primer, Seneschal and colleagues provide an overview of the epidemiology, pathogenesis, diagnosis and management of the condition as well as of its effect on quality of life, and highlight current and emerging treatments.
Keywords:
vitiligo
autoimmune disorder
depigmentation
melanocyte loss
pathogenesis

Journal

N
Nature Reviews Disease Primers
IF:
60.6
Papers:
645
Citations:
3.8W

Organization

I
imrb – paris-est créteil university
Scholars:
1
Papers: 1
Citations: 0
U
umr 5164
Scholars:
6
Papers: 4
Citations: 0
H
Henry Ford Health
Scholars:
262
Papers: 109
Citations: 0
T
the catholic university of korea
Scholars:
1.4K
Papers: 569
Citations: 0
U
University of Massachusetts Chan Medical School
Scholars:
518
Papers: 168
Citations: 2.0W
I
irccs
Scholars:
2.0K
Papers: 611
Citations: 142
G
Ghent University Hospital
Scholars:
8.3K
Papers: 6.6K
Citations: 1.6W
researcher View more organizations